Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10516836 | 0.88 | AGTR2 (0.42) | AGTR2NR1D1CTSLCTSBCTSK | |
| SCHEMBL13868432 | 0.86 | CTSL (0.41) | AGTR2NR1D1CTSLCTSBCTSK | |
| SCHEMBL8478967 | 0.85 | TACR1 (0.40) | AGTR2NR1D1CTSLCTSBCTSK | |
| SCHEMBL3834075 | 0.84 | SIGMAR1 (0.47) | AGTR2LMNA | |
| SCHEMBL7261215 | 0.81 | CTSL (0.49) | CTSLCTSBCTSKTSHRLMNA | |
| SCHEMBL7265611 | 0.81 | CTSL (0.49) | CTSLCTSBCTSKTSHRLMNA | |
| SCHEMBL7261216 | 0.81 | CTSL (0.49) | CTSLCTSBCTSKTSHRLMNA | |
| SCHEMBL7265773 | 0.80 | EGFR (0.45) | CTSLCTSBCTSK | |
| SCHEMBL23802796 | 0.79 | ABCB1 (0.48) | SLC6A9 | |
| SCHEMBL9024007 | 0.77 | NR1D1 (0.39) | AGTR2NR1D1ABHD6DAGLAGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | DHPS, DUT, CDKN1A | AGTR2 2930/4885NR1D1 2889/4885CTSL 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.